These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

129 related articles for article (PubMed ID: 34031538)

  • 1. Increased chemosensitivity via BRCA2-independent DNA damage in DSS1- and PCID2-depleted breast carcinomas.
    Gondo N; Sakai Y; Zhang Z; Hato Y; Kuzushima K; Phimsen S; Kawashima Y; Kuroda M; Suzuki M; Okada S; Iwata H; Toyama T; Rezano A; Kuwahara K
    Lab Invest; 2021 Aug; 101(8):1048-1059. PubMed ID: 34031538
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Breast cancers with high DSS1 expression that potentially maintains BRCA2 stability have poor prognosis in the relapse-free survival.
    Rezano A; Kuwahara K; Yamamoto-Ibusuki M; Kitabatake M; Moolthiya P; Phimsen S; Suda T; Tone S; Yamamoto Y; Iwase H; Sakaguchi N
    BMC Cancer; 2013 Dec; 13():562. PubMed ID: 24289229
    [TBL] [Abstract][Full Text] [Related]  

  • 3. BRCA2 prevents R-loop accumulation and associates with TREX-2 mRNA export factor PCID2.
    Bhatia V; Barroso SI; García-Rubio ML; Tumini E; Herrera-Moyano E; Aguilera A
    Nature; 2014 Jul; 511(7509):362-5. PubMed ID: 24896180
    [TBL] [Abstract][Full Text] [Related]  

  • 4. DSS1 is required for the stability of BRCA2.
    Li J; Zou C; Bai Y; Wazer DE; Band V; Gao Q
    Oncogene; 2006 Feb; 25(8):1186-94. PubMed ID: 16205630
    [TBL] [Abstract][Full Text] [Related]  

  • 5. DSS1 allosterically regulates the conformation of the tower domain of BRCA2 that has dsDNA binding specificity for homologous recombination.
    Alagar S; Bahadur RP
    Int J Biol Macromol; 2020 Dec; 165(Pt A):918-929. PubMed ID: 33011260
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Promotion of BRCA2-Dependent Homologous Recombination by DSS1 via RPA Targeting and DNA Mimicry.
    Zhao W; Vaithiyalingam S; San Filippo J; Maranon DG; Jimenez-Sainz J; Fontenay GV; Kwon Y; Leung SG; Lu L; Jensen RB; Chazin WJ; Wiese C; Sung P
    Mol Cell; 2015 Jul; 59(2):176-87. PubMed ID: 26145171
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The proteasome is involved in determining differential utilization of double-strand break repair pathways.
    Gudmundsdottir K; Lord CJ; Ashworth A
    Oncogene; 2007 Nov; 26(54):7601-6. PubMed ID: 17563742
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Conformational stability of PCID2 upon DSS1 binding with molecular dynamics simulation.
    Liu Q; Hu G; Cao Z; Wang J; Chen H
    J Mol Model; 2015 May; 21(5):127. PubMed ID: 25914122
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interaction between the product of the breast cancer susceptibility gene BRCA2 and DSS1, a protein functionally conserved from yeast to mammals.
    Marston NJ; Richards WJ; Hughes D; Bertwistle D; Marshall CJ; Ashworth A
    Mol Cell Biol; 1999 Jul; 19(7):4633-42. PubMed ID: 10373512
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Depletion of DSS1 protein disables homologous recombinational repair in human cells.
    Kristensen CN; Bystol KM; Li B; Serrano L; Brenneman MA
    Mutat Res; 2010 Dec; 694(1-2):60-4. PubMed ID: 20817001
    [TBL] [Abstract][Full Text] [Related]  

  • 11. DSS1 restrains BRCA2's engagement with dsDNA for homologous recombination, replication fork protection, and R-loop homeostasis.
    Huang Y; Li W; Foo T; Ji JH; Wu B; Tomimatsu N; Fang Q; Gao B; Long M; Xu J; Maqbool R; Mukherjee B; Ni T; Alejo S; He Y; Burma S; Lan L; Xia B; Zhao W
    Nat Commun; 2024 Aug; 15(1):7081. PubMed ID: 39152168
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Human TREX2 components PCID2 and centrin 2, but not ENY2, have distinct functions in protein export and co-localize to the centrosome.
    Cunningham CN; Schmidt CA; Schramm NJ; Gaylord MR; Resendes KK
    Exp Cell Res; 2014 Jan; 320(2):209-18. PubMed ID: 24291146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Cancer-causing BRCA2 missense mutations disrupt an intracellular protein assembly mechanism to disable genome maintenance.
    Lee M; Shorthouse D; Mahen R; Hall BA; Venkitaraman AR
    Nucleic Acids Res; 2021 Jun; 49(10):5588-5604. PubMed ID: 33978741
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic exploitation of tumor cell defects in homologous recombination.
    Powell SN; Kachnic LA
    Anticancer Agents Med Chem; 2008 May; 8(4):448-60. PubMed ID: 18473729
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced RAD21 cohesin expression confers poor prognosis and resistance to chemotherapy in high grade luminal, basal and HER2 breast cancers.
    Xu H; Yan M; Patra J; Natrajan R; Yan Y; Swagemakers S; Tomaszewski JM; Verschoor S; Millar EK; van der Spek P; Reis-Filho JS; Ramsay RG; O'Toole SA; McNeil CM; Sutherland RL; McKay MJ; Fox SB
    Breast Cancer Res; 2011 Jan; 13(1):R9. PubMed ID: 21255398
    [TBL] [Abstract][Full Text] [Related]  

  • 16. DSS1 and ssDNA regulate oligomerization of BRCA2.
    Le HP; Ma X; Vaquero J; Brinkmeyer M; Guo F; Heyer WD; Liu J
    Nucleic Acids Res; 2020 Aug; 48(14):7818-7833. PubMed ID: 32609828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. DSS1 is required for RAD51 focus formation and genomic stability in mammalian cells.
    Gudmundsdottir K; Lord CJ; Witt E; Tutt AN; Ashworth A
    EMBO Rep; 2004 Oct; 5(10):989-93. PubMed ID: 15359272
    [TBL] [Abstract][Full Text] [Related]  

  • 18. BRCA1 alterations with additional defects in DNA damage response genes may confer chemoresistance to BRCA-like breast cancers treated with neoadjuvant chemotherapy.
    Takada M; Nagai S; Haruta M; Sugino RP; Tozuka K; Takei H; Ohkubo F; Inoue K; Kurosumi M; Miyazaki M; Sato-Otsubo A; Sato Y; Ogawa S; Kaneko Y
    Genes Chromosomes Cancer; 2017 May; 56(5):405-420. PubMed ID: 28124401
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced RAD21 cohesin expression confers poor prognosis in BRCA2 and BRCAX, but not BRCA1 familial breast cancers.
    Yan M; Xu H; Waddell N; Shield-Artin K; Haviv I; ; McKay MJ; Fox SB
    Breast Cancer Res; 2012 Apr; 14(2):R69. PubMed ID: 22537934
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhancement of synthetic lethality via combinations of ABT-888, a PARP inhibitor, and carboplatin in vitro and in vivo using BRCA1 and BRCA2 isogenic models.
    Clark CC; Weitzel JN; O'Connor TR
    Mol Cancer Ther; 2012 Sep; 11(9):1948-58. PubMed ID: 22778154
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.